Transitioning between automated insulin delivery systems: A focus on personalisation
Authors' conclusion
Transitioning between AID systems can enhance glucose control and user satisfaction without compromising glycaemic stability during the adjustment period.
Study context
- Population
- T1D subjects who had switched between automated insulin delivery (AID) systems (MiniMedTM-780G, Diabeloop-DBLG1, Tandem-t:slim-x2TM-Control-IQTM, CamAPS-FX); age 40.8 ± 11.5 years, 73 % female, HbA1c 6.94 ± 0.68 %
- Participants
- 96 subjects
- Exposure
- Before vs after switching between AID systems
- Outcome
- Impact of switching between AID systems on glucose control and user satisfaction
- Follow-up
- 14 days and 3 months
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
GMI
After 14 days vs Before switch: P < 0.001 to baseline · After 3 months vs Before switch: P < 0.001 to baseline
Observational data: associations, not effects.
Further findings
| Outcome | Before switch | P value |
|---|---|---|
| TIR 70-180 mg/dl · 14 days and 3 monthsAfter 14 days vs Before switch | 70.53 ± 11.43 % | P < 0.001 to baseline |
| TIR 70-180 mg/dl · 14 days and 3 monthsAfter 3 months vs Before switch | P < 0.001 to baseline |
- TIR 70-180 mg/dl: After 14 days 75.73 ± 8.33 %
- TIR 70-180 mg/dl: After 3 months 75.65 ± 7.64 %
User satisfaction
- The majority of participants reported higher satisfaction
- Factors most affecting satisfaction: system size, sensor performance, control algorithm specificities
Original publication
Transitioning between automated insulin delivery systems: A focus on personalisation. Diabetes Res Clin Pract. Published 26 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →